CARI Guidelines: Australian and New Zealand living guideline for pharmacological management of autosomal dominant polycystic kidney disease

Published by David Tunnicliffe on Jul 26, 2023

Disclaimer

Sponsors

Contact

Abstract

Language

en

PICOS

PICO 1.1

Population
Autosomal dominant polycystic kidney disease
Intervention
ACEi
Comparator
No treatment
Outcomes

PICO 1.2

Population
Interventions for preventing the progression of autosomal dominant polycystic kidney disease
Intervention
ACEi
Comparator
CCB
Outcomes

PICO 1.3

Population
Interventions for preventing the progression of autosomal dominant polycystic kidney disease
Intervention
ACEi
Comparator
ARB
Outcomes

PICO 1.4

Population
Autosomal dominant polycystic kidney disease
Intervention
ACEi
Comparator
beta-blockers
Outcomes

PICO 1.5

Population
Autosomal dominant polycystic kidney disease
Intervention
ARB
Comparator
CCB
Outcomes

PICO 1.6

Population
Interventions for preventing the progression of autosomal dominant polycystic kidney disease
Intervention
ACEi + ARB
Comparator
ACEi
Outcomes

PICO 1.7

Population
Interventions for preventing the progression of autosomal dominant polycystic kidney disease
Intervention
ACEi alone
Comparator
ACEi + mTOR inhibitors
Outcomes

PICO 1.8

Population
Interventions for preventing the progression of autosomal dominant polycystic kidney disease
Intervention
ARB alone
Comparator
ARB + mTOR inhibitors
Outcomes

PICO 1.9

Population
Interventions for preventing the progression of autosomal dominant polycystic kidney disease
Intervention
Tolvaptan
Comparator
Placebo
Outcomes

PICO 1.10

Population
Interventions for preventing the progression of autosomal dominant polycystic kidney disease
Intervention
High
Comparator
low dose V2R antagonists
Outcomes

PICO 1.11

Population
Interventions for preventing the progression of autosomal dominant polycystic kidney disease
Intervention
mTOR inhibitors
Comparator
no treatment
Outcomes

PICO 1.12

Population
Interventions for preventing the progression of autosomal dominant polycystic kidney disease
Intervention
Somatostatin analogues
Comparator
placebo
Outcomes

PICO 1.13

Population
Interventions for preventing the progression of autosomal dominant polycystic kidney disease
Intervention
Somatostatin analogues + mTOR inhibitors
Comparator
somatostatin analogues alone
Outcomes

PICO 1.14

Population
Interventions for preventing the progression of autosomal dominant polycystic kidney disease
Intervention
Antiplatelet agents
Comparator
placebo
Outcomes

PICO 1.15

Population
Interventions for preventing the progression of autosomal dominant polycystic kidney disease
Intervention
Eicosapentaenoic acids
Comparator
standard therapy
Outcomes

PICO 1.16

Population
Interventions for preventing the progression of autosomal dominant polycystic kidney disease
Intervention
Statins
Comparator
no treatment
Outcomes

PICO 1.17

Population
Interventions for preventing the progression of autosomal dominant polycystic kidney disease
Intervention
Metformin
Comparator
placebo
Outcomes

PICO 1.18

Population
Interventions for preventing the progression of autosomal dominant polycystic kidney disease
Intervention
Vitamin D
Comparator
traditional Chinese herbal medicine
Outcomes